Will the price of dacomitinib/dacomitinib be reduced in 2024?

Dacomitinib/Dacomitinib (Dacomitinib) is a second-generation irreversible EGFR tyrosine kinase inhibitor that also has activity against ErbB family members and therefore can be considered a pan-ErbB inhibitor. Dacotinib has good bioavailability greater than 50% and a long half-life (>12 hours), but its toxicity is slightly higher than that of the first-generation EGFR inhibitors. Because dacomitinib showed significant improvement compared with gefitinib, dacomitinib has been registered for first-line treatment of patients with non-small cell lung cancer with activating mutations in EGFR. Dacotinib may be used in combination with conventional chemotherapy or specifically with monoclonal antibodies targeting the EGFR receptor. Dacomitinib has shown brain penetration in preclinical models and should therefore be studied in patients with CNS metastases. Dacomitinib is also being evaluated as a second-line treatment in patients who are resistant to osimertinib as a first-line treatment.

The original drug Dacomitinib can be purchased in China and has been included in the Class B medical insurance drugs, which gives many patients hope. Usually, a box of 30 tablets of 15mg dacomitinib is sold in China for about more than 1,000 yuan. If you are overseas, you may find that the European version of dacomitinib, available in 45 mg and 30 tablets, costs more than 20,000 yuan, and this price will fluctuate with changes in the exchange rate. Fortunately, overseas markets also offer more affordable generic drug options. For example, a dacomitinib generic drug produced in Laos has the same specifications of 45mg*30 tablets, but the price is only about 800 yuan. Although the price may fluctuate due to exchange rate changes, its price advantage is still very obvious compared to the original drug.